Affinity Asset Advisors, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Affinity Asset Advisors, LLC reported 70 stock positions worth $601.0 million. Its top holding was Xenon Pharmaceuticals (XENE) at 7.5% of the portfolio, followed by Apogee Therapeutics (APGE, 6.5%) and Nuvalent Class A (NUVL, 5.7%). Compared with Q2 2024, it opened 10 new positions, sold out of 18, added to 19 and reduced 28. The biggest buy was Nuvalent Class A (NUVL, shares +69%) and the biggest sale an exit from Cerevel Therapeutics (CERE).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001773195
- Portfolio Value
- $601.0M (Q3 2024)
- SEC Filing
- 0001839882-24-038904 ↗ filed Nov 13, 2024
Holdings Value
Holdings 70 stocks · $601.0M
| XENE Xenon Pharmaceuticals Inc. | 7.49% | 1,144,021 | $45.0M | Add +15.1% |
| APGE Apogee Therapeutics Inc. | 6.49% | 664,198 | $39.0M | Reduce -20.6% |
| NUVL Nuvalent Inc. Class A | 5.75% | 337,500 | $34.5M | Add +68.8% |
| ACLX Arcellx Inc. | 5.56% | 400,000 | $33.4M | Reduce -13.0% |
| ALKS Alkermes PLC | 4.66% | 1,000,000 | $28.0M | Add +53.9% |
| TEVA Teva Pharmaceutical-SP ADR | 4.20% | 1,400,000 | $25.2M | Reduce -3.5% |
| MDGL Madrigal Pharmaceuticals Inc. | 3.53% | 100,000 | $21.2M | Reduce -9.1% |
| CRNX Crinetics Pharmaceuticals Inc. | 3.40% | 400,000 | $20.4M | Reduce -22.3% |
| NRIX Nurix Therapeutics Inc. | 3.22% | 860,399 | $19.3M | Reduce -5.7% |
| VERA Vera Therapeutics Inc. | 3.20% | 435,000 | $19.2M | Add +16.0% |
| VRNA Verona Pharma Ltd. | 3.11% | 650,000 | $18.7M | Reduce -7.1% |
| AUTL Autolus Therapeutics PLC | 2.72% | 4,500,000 | $16.3M | Add +4.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.57% | 965,612 | $15.4M | Reduce -15.0% |
| INZY Inozyme Pharma Inc. | 2.46% | 2,822,318 | $14.8M | Reduce -1.2% |
| SYRE Spyre Therapeutics Inc. | 2.44% | 498,420 | $14.7M | Reduce -2.9% |
| KURA Kura Oncology Inc. | 2.24% | 687,785 | $13.4M | Add +5.8% |
| ESTA Establishment Labs Holdings | 2.09% | 290,447 | $12.6M | Add +30.0% |
| VRDN Viridian Therapeutics Inc. | 1.99% | 525,000 | $11.9M | Add +250.0% |
| WVE Wave Life Sciences Ltd. | 1.91% | 1,400,000 | $11.5M | Add +273.3% |
| ORKA Oruka Therapeutics Inc. | 1.43% | 349,836 | $8.6M | New |
| RZLT Rezolute Inc. | 1.37% | 1,700,000 | $8.2M | Reduce -8.1% |
| MRUS Merus NV | 1.34% | 161,741 | $8.1M | Add +29.4% |
| ATXS Astria Therapeutics Inc. | 1.33% | 725,106 | $8.0M | Reduce -25.7% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 1.31% | 35,000 | $7.9M | Reduce -68.2% |
| NAMS Newamsterdam Pharma Co. NV | 1.30% | 472,390 | $7.8M | Add +11.6% |
| BBIO Bridgebio Pharma Inc. | 1.27% | 300,000 | $7.6M | Add +200.0% |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 1.27% | 1,500,000 | $7.6M | Reduce -10.2% |
| AXSM Axsome Therapeutics Inc. | 1.20% | 80,000 | $7.2M | No change |
| ERAS Erasca Inc. | 1.14% | 2,499,431 | $6.8M | No change |
| GERN Geron Corp. | 1.13% | 1,500,000 | $6.8M | No change |
| CATX Perspective Therapeutics Inc. | 1.11% | 500,000 | $6.7M | Reduce -9.1% |
| IMVT Immunovant Inc. | 1.07% | 225,000 | $6.4M | Reduce -35.0% |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.05% | 325,000 | $6.3M | Add +550.0% |
| PCVX Vaxcyte Inc. | 0.95% | 50,000 | $5.7M | Reduce -16.7% |
| ARVN Arvinas Inc. | 0.92% | 225,000 | $5.5M | New |
| TERN Terns Pharmaceuticals Inc. | 0.83% | 600,000 | $5.0M | New |
| SWTX Springworks Therapeutics Inc. | 0.79% | 147,500 | $4.7M | Add +110.7% |
| CGEM Cullinan Therapeutics Inc. | 0.73% | 263,817 | $4.4M | No change |
| CLDX Celldex Therapeutics Inc. | 0.71% | 125,000 | $4.2M | Reduce -73.7% |
| MLYS Mineralys Therapeutics Inc. | 0.71% | 350,000 | $4.2M | Add +6.7% |
| INSM Insmed Inc. | 0.61% | 50,000 | $3.6M | Reduce -60.0% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.58% | 350,000 | $3.5M | No change |
| NXTC Nextcure Inc. | 0.52% | 2,302,598 | $3.2M | Add +36.4% |
| SVRA Savara Inc. | 0.49% | 700,000 | $3.0M | Reduce -54.8% |
| NKTX Nkarta Inc. | 0.49% | 650,000 | $2.9M | Add +225.0% |
| MIRM Mirum Pharmaceuticals Inc. | 0.49% | 75,000 | $2.9M | Reduce -51.6% |
| IMTX Immatics NV | 0.47% | 250,000 | $2.9M | Reduce -16.7% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.43% | 250,000 | $2.6M | No change |
| CNTX Context Therapeutics Inc. | 0.43% | 1,321,153 | $2.6M | Reduce -18.4% |
| NARI Inari Medical Inc. | 0.41% | 60,000 | $2.5M | Reduce -70.0% |
| ROIV Roivant Sciences Ltd. | 0.39% | 201,587 | $2.3M | Reduce -42.7% |
| KEZAR LIFE SCIENCES INC | 0.32% | 2,511,778 | $1.9M | Add +42.6% |
| CMPS Compass Pathways PLC | 0.32% | 300,512 | $1.9M | Reduce -40.0% |
| TECX Tectonic Therapeutic Inc. | 0.29% | 58,331 | $1.8M | No change |
| SLNO Soleno Therapeutics Inc. | 0.21% | 25,000 | $1.3M | New |
| AEROVATE THERAPEUTICS INC | 0.21% | 600,000 | $1.3M | Add +200.0% |
| QTTB Q32 Bio Inc. | 0.21% | 27,777 | $1.2M | No change |
| VSTM Verastem Inc. | 0.20% | 400,000 | $1.2M | New |
| BMRN Biomarin Pharmaceutical Inc. | 0.18% | 15,000 | $1.1M | New |
| ZURA Zura Bio Ltd. | 0.15% | 223,335 | $907K | No change |
| PBYI Puma Biotechnology Inc. | 0.11% | 250,000 | $638K | No change |
| RPTX Repare Therapeutics Inc. | 0.10% | 173,351 | $596K | New |
| KYTX Kyverna Therapeutics Inc. | 0.10% | 119,900 | $586K | Reduce -40.0% |
| ADGM Adagio Medical Holdings Inc. | 0.09% | 213,235 | $550K | New |
| AVTX Avalo Therapeutics Inc. | 0.07% | 45,000 | $426K | No change |
| VYGR Voyager Therapeutics Inc. | 0.05% | 51,727 | $303K | New |
| MTVA Metavia Inc. filed as NEUROBO PHARMACEUTICALS INC | 0.05% | 89,222 | $283K | No change |
| GNLX Genelux Corp. | 0.04% | 100,000 | $237K | No change |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 0.02% | 47,019 | $97K | New |
| PMN Promis Neurosciences Inc. | 0.01% | 30,643 | $38K | Reduce -88.5% |
Options reported separately and not counted above: FLNA puts ($42.7M), TEVA calls ($18.0M), ANAB puts ($6.7M), SPRY calls ($5.8M), NVAX calls ($3.8M), GALT puts ($3.3M), SMMT calls ($3.1M), SYRS puts ($2.7M), IMVT calls ($2.2M).
Other holdings (7): bonds, preferreds, convertibles and warrants · $43.6M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | 21,525,000 | $14.6M | Add +88.0% |
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | 16,625,000 | $13.1M | Add +41.5% |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | 12,250,000 | $9.6M | Add +25.6% |
| TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29) | NOTE 2.250% 3/0 · principal | 5,000,000 | $4.3M | New |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 212,974 | $1.5M | Add +5.1% |
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | 187,204 | $431K | No change |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 75,000 | $5K | No change |
Total filed on the 13F, all lines: $644.5M.
Portfolio Sells Q2 2024 → Q3 2024
| CERE Cerevel Therapeutics Holding | Sold out | 0.00% | −3.55 |
| CLDX Celldex Therapeutics Inc. | Reduce -73.7% | 0.71% | −2.35 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -9.1% | 3.53% | −1.82 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −1.48 |
| ONC Beone Medicines Ltd.-ADR | Reduce -68.2% | 1.31% | −1.42 |
| NARI Inari Medical Inc. | Reduce -70.0% | 0.41% | −1.26 |
| INSM Insmed Inc. | Reduce -60.0% | 0.61% | −0.85 |
| CLYM Climb Bio Inc. | Reduce -10.2% | 1.27% | −0.79 |
| ELEV Elevation Oncology Inc. | Sold out | 0.00% | −0.69 |
| HLVX Hillevax Inc. | Sold out | 0.00% | −0.67 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.61 |
| XBI SS SPDR S&P Biotech ETF | Sold out | 0.00% | −0.60 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -22.3% | 3.40% | −0.60 |
| SVRA Savara Inc. | Reduce -54.8% | 0.49% | −0.59 |
| BDTX Black Diamond Therapeutics I | Sold out | 0.00% | −0.53 |
| IMVT Immunovant Inc. | Reduce -35.0% | 1.07% | −0.52 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −0.52 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -51.6% | 0.49% | −0.43 |
| VIR Vir Biotechnology Inc. | Sold out | 0.00% | −0.31 |
| ZYME Zymeworks Inc. | Sold out | 0.00% | −0.28 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −0.27 |
| ARYD Arya Sciences Acquisition-A | Sold out | 0.00% | −0.27 |
| ADCT Adc Therapeutics SA | Sold out | 0.00% | −0.26 |
| ROIV Roivant Sciences Ltd. | Reduce -42.7% | 0.39% | −0.26 |
| TNGX Tango Therapeutics Inc. | Sold out | 0.00% | −0.22 |
| ATXS Astria Therapeutics Inc. | Reduce -25.7% | 1.33% | −0.21 |
| CMPS Compass Pathways PLC | Reduce -40.0% | 0.32% | −0.21 |
| KYTX Kyverna Therapeutics Inc. | Reduce -40.0% | 0.10% | −0.16 |
| CNTX Context Therapeutics Inc. | Reduce -18.4% | 0.43% | −0.13 |
| IMTX Immatics NV | Reduce -16.7% | 0.47% | −0.13 |
| NRIX Nurix Therapeutics Inc. | Reduce -5.7% | 3.22% | −0.09 |
| PMN Promis Neurosciences Inc. | Reduce -88.5% | 0.01% | −0.06 |
| ARCA BIOPHARMA INC | Sold out | 0.00% | −0.05 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −0.04 |
| PASG Passage Bio Inc. | Sold out | 0.00% | −0.04 |
| RZLT Rezolute Inc. | Reduce -8.1% | 1.37% | −0.01 |
| IOVA Iovance Biotherapeutics Inc. | Sold out | 0.00% | −0.00 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -3.5% | 4.20% | +0.11 |
| CATX Perspective Therapeutics Inc. | Reduce -9.1% | 1.11% | +0.16 |
| PCVX Vaxcyte Inc. | Reduce -16.7% | 0.95% | +0.16 |
| INZY Inozyme Pharma Inc. | Reduce -1.2% | 2.46% | +0.24 |
| SYRE Spyre Therapeutics Inc. | Reduce -2.9% | 2.44% | +0.34 |
| APGE Apogee Therapeutics Inc. | Reduce -20.6% | 6.49% | +0.78 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -15.0% | 2.57% | +0.79 |
| ACLX Arcellx Inc. | Reduce -13.0% | 5.56% | +1.15 |
| VRNA Verona Pharma Ltd. | Reduce -7.1% | 3.11% | +1.35 |
Portfolio Buys Q2 2024 → Q3 2024
| NUVL Nuvalent Inc. Class A | Add +68.8% | 5.75% | +3.11 |
| ALKS Alkermes PLC | Add +53.9% | 4.66% | +1.94 |
| VRDN Viridian Therapeutics Inc. | Add +250.0% | 1.99% | +1.65 |
| WVE Wave Life Sciences Ltd. | Add +273.3% | 1.91% | +1.59 |
| ORKA Oruka Therapeutics Inc. | New | 1.43% | +1.43 |
| ARVN Arvinas Inc. | New | 0.92% | +0.92 |
| VERA Vera Therapeutics Inc. | Add +16.0% | 3.20% | +0.84 |
| TERN Terns Pharmaceuticals Inc. | New | 0.83% | +0.83 |
| BBIO Bridgebio Pharma Inc. | Add +200.0% | 1.27% | +0.83 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +550.0% | 1.05% | +0.82 |
| XENE Xenon Pharmaceuticals Inc. | Add +15.1% | 7.49% | +0.76 |
| ESTA Establishment Labs Holdings | Add +30.0% | 2.09% | +0.33 |
| SWTX Springworks Therapeutics Inc. | Add +110.7% | 0.79% | +0.33 |
| NKTX Nkarta Inc. | Add +225.0% | 0.49% | +0.28 |
| SLNO Soleno Therapeutics Inc. | New | 0.21% | +0.21 |
| VSTM Verastem Inc. | New | 0.20% | +0.20 |
| BMRN Biomarin Pharmaceutical Inc. | New | 0.18% | +0.18 |
| AEROVATE THERAPEUTICS INC | Add +200.0% | 0.21% | +0.15 |
| KEZAR LIFE SCIENCES INC | Add +42.6% | 0.32% | +0.14 |
| AUTL Autolus Therapeutics PLC | Add +4.7% | 2.72% | +0.12 |
| RPTX Repare Therapeutics Inc. | New | 0.10% | +0.10 |
| ADGM Adagio Medical Holdings Inc. | New | 0.09% | +0.09 |
| MRUS Merus NV | Add +29.4% | 1.34% | +0.06 |
| NXTC Nextcure Inc. | Add +36.4% | 0.52% | +0.06 |
| VYGR Voyager Therapeutics Inc. | New | 0.05% | +0.05 |
| MLYS Mineralys Therapeutics Inc. | Add +6.7% | 0.71% | +0.04 |
| WHWK Whitehawk Therapeutics Inc. | New | 0.02% | +0.02 |
| KURA Kura Oncology Inc. | Add +5.8% | 2.24% | −0.09 |
| NAMS Newamsterdam Pharma Co. NV | Add +11.6% | 1.30% | −0.11 |
Options Activity Q2 2024 → Q3 2024
| SPY SS SPDR S&P 500 ETF Trust-US | put | Sold out | 350,000 | $190.5Mbefore exit |
| FLNA Filana Therapeutics Inc. | put | New | 1,449,300 | $42.7M |
| TEVA Teva Pharmaceutical-SP ADR | call | Reduce -13.0% | 1,000,000 | $18.0M |
| CERE Cerevel Therapeutics Holding | call | Sold out | 250,000 | $10.2Mbefore exit |
| ANAB Anaptysbio Inc. | put | New | 200,000 | $6.7M |
| SPRY Ars Pharmaceuticals Inc. | call | New | 400,000 | $5.8M |
| NVAX Novavax Inc. | call | New | 300,000 | $3.8M |
| GALT Galectin Therapeutics Inc. | put | New | 1,211,400 | $3.3M |
| SMMT Summit Therapeutics Inc. | call | New | 140,000 | $3.1M |
| SANA Sana Biotechnology Inc. | put | Sold out | 521,000 | $2.8Mbefore exit |
| SYRS Syros Pharmaceuticals Inc. | put | New | 1,234,200 | $2.7M |
| IMVT Immunovant Inc. | call | Add +43.6% | 78,000 | $2.2M |
| TWST Twist Bioscience Corp. | call | Sold out | 45,000 | $2.2Mbefore exit |
| RAPT THERAPEUTICS INC | put | Sold out | 545,000 | $1.7Mbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | Sold out | 250,000 | $1.6Mbefore exit |
| IOVA Iovance Biotherapeutics Inc. | put | Sold out | 150,000 | $1.2Mbefore exit |
| PCVX Vaxcyte Inc. | call | Sold out | 15,000 | $1.1Mbefore exit |
| ALXO Alx Oncology Holdings Inc. | call | Sold out | 100,000 | $603Kbefore exit |
| INSM Insmed Inc. | put | Sold out | 8,700 | $583Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q2 2024 → Q3 2024
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | Sold out | 17,000,000 | $17.3Mbefore exit |
| ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27) | NOTE 1.000% 9/1 · principal | Sold out | 15,000,000 | $16.2Mbefore exit |
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | Add +88.0% | 21,525,000 | $14.6M |
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | Add +41.5% | 16,625,000 | $13.1M |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | Add +25.6% | 12,250,000 | $9.6M |
| TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29) | NOTE 2.250% 3/0 · principal | New | 5,000,000 | $4.3M |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | Add +5.1% | 212,974 | $1.5M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $2.0B | ROIV, APGE, SYRE, XENE, ERAS |
| Q1 2026 | 90 | $1.7B | APGE, XENE, ERAS, INSM, ROIV |
| Q4 2025 | 80 | $1.3B | APGE, INSM, ABVX, VTYX, XENE |
| Q3 2025 | 80 | $1.0B | VRNA, INSM, SPY, XENE, MDGL |
| Q2 2025 | 71 | $648.9M | VRNA, INSM, XENE, ACLX, BPMC |
| Q1 2025 | 75 | $603.1M | XENE, APGE, VRNA, ACLX, ALKS |
| Q4 2024 | 68 | $588.3M | XENE, APGE, ACLX, ALKS, TEVA |
| Q3 2024 | 70 | $601.0M | XENE, APGE, NUVL, ACLX, ALKS |
| Q2 2024 | 78 | $576.0M | XENE, APGE, MDGL, ACLX, TEVA |
| Q1 2024 | 69 | $571.1M | APGE, XENE, MDGL, CRNX, AUTL |